This research reviews the available literature about 5-MeO-DMT and informs subsequent clinical development.
Read morePsilocybin-assisted Therapy
From Johns Hopkins Psychedelic Newsletter Fall 2021:
Last year, Dr. Frederick Barrett published a study that showed psilocybin reduced neural activity in the claustrum during the period of drug action.
The claustrum, once thought to be the seat of consciousness, is a thin sheet of gray matter in the brain that reaches out to every other region in the brain.
The results showed that both the default mode network and areas of the brain believed to be responsible for setting attention and switching tasks may be disrupted during the effects of psilocybin, and alterations in the claustrum may account for these changes.
Read moreMore Research Coming!
Well this is exciting: The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.
Read moreInterview with Rick Doblin
Keep reading for an interview with pioneering psychedelic activist Rick Doblin about the promise of MDMA therapy for PTSD, working with Republicans, and his hope for a drug-assisted global spiritual awakening.
Read morePodcast on Psychedelics
Podcast on psychedelics: the science, research, and medical implications with Dr. Fred Barrett.
Dr. Frederick Barrett is a cognitive neuroscientist with training in behavioral pharmacology. He has been conducting psychedelic research at Johns Hopkins University since 2013. He has explored the effects of psilocybin on the brain, the effects of LSD on the brain’s response to music, and is currently leading a number of ongoing studies aimed at better understanding the psychological, biological, and neural mechanisms underlying the therapeutic efficacy of psychedelic drugs.
Read morePsychedelics: Highs and Lows
MDMA Therapy Revolution
"I hope in the big picture, by 2050, we'll have enough people with an understanding of how to use psychedelics for personal, emotional, and spiritual growth that we'll have a more spiritualized humanity to turn us more towards saving the planet from mass weapons, climate change, and prejudice," explains Doblin.
Read moreBBC Future profile on Psychedelics
By highlighting the rapid increase in psychedelic research over the past ten years, Ed Prideaux of BBC explains how clinical trial results, favorable media coverage, and the potential development of new mental health treatments are steadily moving the public perception of psychedelics toward mainstream acceptance.
"Now the efforts of Doblin and others are finally paying off,” writes Prideaux. "Promising clinical trials suggest that psychedelics may prove game-changing treatments for depression, PTSD and addiction."
Read moreYale Research on Psilocybin
Yale researchers discover healing effects of psychedelic drug psilocybin.
Researchers find that one dose of psilocybin results in roughly a 10 percent increase in neuron size and density in mouse brains.
Read moreKetamine and Your Brain
What does ketamine do to your brain?
Much of how ketamine works is a mystery, but the picture is slowly coming into focus.
Read moreAre Doctors Ready for Psychedelics?
Psychedelic treatments are here, but doctors aren’t prepared.
So says Rick Doblin, founder and executive director of the Multidisciplinary Assn. for Psychedelic Studies.
Read more